

Nil

File No. FDC/MA/23/000242
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organization
(FDC Division)

Tele. No.:011-23236965
Fax No. :011-23236973

FDA Bhawan, Kotla Road
New Delhi-110002

Dated: 01-Oct-2024

To,

M/s. Glenmark Pharmaceuticals Limited,
B2, Mahalaxmi Chambers, 22 Bhula Bhai,
Desai Road Mumbai, Maharashtra-400026.

Subject: Permission to conduct Phase III clinical trial with the FDC of Glycopyrronium + Formoterol Fumarate + Budesonide (25mcg + 20mcg + 0.5mg) Inhalation Suspension (Vide protocol no. GPL/CT/2024/002/III, version no. 2.0, dated: 28.05.2024)-regarding.

Dear Sir,

With reference to your online application submitted in Form CT-04 on dated 18.07.2024 please find enclosed herewith the "permission to conduct clinical trial study of new drug" bearing no. **FDC-CT-06-37/2024** under the provision of Drugs and Cosmetics Act and Rules. The permission is subject to the conditions mentioned below.

Kindly acknowledge receipt to this letter and its enclosures.

RAJEEV SINGH
RAGHUVANSHI

Digitally signed by RAJEEV SINGH RAGHUVANSHI
DN: c=IN, o=CENTRAL DRUGS STANDARD CONTROL ORGANISATION, ou=CENTRAL LICENSING AUTHORITY, ou=CONTROL ORGANISATION, 2.5.4.20=42d718961e0981ba5c2623457340259f8b11b680a9108773480900a43ec361b, postalCode=110002, st=Delhi, serialNumber=657f5e47d940985d8f03bd4c902d0e1e73c817a1a126ea9f6a5701124a19013, cn=RAJEEV SINGH RAGHUVANSHI
Date: 2024.10.01 15:08:32 +05'30'

(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India)

CONDITIONS OF PERMISSION

- I. Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licencing Authority under rule 8;
- II. Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:
 - i. Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be;
 - ii. Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;
- III. In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licencing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site; The Central Licencing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;
- IV. Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;
- V. Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;

- VI. Status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;
- VII. Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licencing Authority electronically in the SUGAM portal;
- VIII. In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination;
- IX. Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licencing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI;
- X. In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licencing Authority in accordance with the provisions of the said Chapter;
- XI. In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of receipt of the order issued by the Central Licencing Authority in accordance with the provisions of the said Chapter;
- XII. The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorised by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;
- XIII. Where the new drug or investigational new drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;
- XIV. The laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licencing Authority and may be used for test or analysis of any drug for and on behalf of Central Licencing Authority;
- XV. The Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;
- XVI. The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.
- XVII. The formulation intended to be used in the clinical trial study shall be manufactured under GMP conditions using validated procedures.
- XVIII. It may kindly be noted that merely granting permission to conduct Clinical trials/Bioavailability or Bioequivalence study with the drug does not convey or imply that, based on the Clinical trial data/ Bioavailability or Bioequivalence study data generated with the drug, permission to market this drug in the country will automatically be granted to you.
- XIX. **The firm should submit Phase III clinical trial report to CDSCO for further review by the committee.**

FORM CT-06

(See rules 22, 25, 26, 29 and 30)

**PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR
INVESTIGATIONAL NEW DRUG****Permission no.: FDC-CT-06-37/2024**

1. The Central Licencing Authority hereby permits **M/s. Glenmark Pharmaceuticals Limited, B2, Mahalaxmi Chambers, 22 Bhula Bhai, Desai Road Mumbai, Maharashtra-400026., Telephone No: 2240189999, Fax: 2240189988, E-mail: kishansingh.kaira@glenmarkpharma.com** to conduct clinical trial of the new drug or investigational new drug as per protocol number (**GPL/CT/2024/002/III, version no. 2.0, dated: 28.05.2024**) in the below mentioned clinical trial sites.
2. Details of new drug or investigational new drug and clinical trial site [As per Annexure].
3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

**RAJEEV SINGH
RAGHUVANSHI**

Digitally signed by RAJEEV SINGH RAGHUVANSHI
DN: c=IN, o=CENTRAL DRUGS STANDARD CONTROL
ORGANISATION, ou=CENTRAL DRUGS STANDARD
CONTROL ORGANISATION,
2.5.4.20=f2d718181c09812b6a7634a748073818112680a
9158f72488400a41e0361e, postalCode=110002, st=Delhi,
serialNumber=65751e14519195d8f03d3c02956167757a1
2a1a126ea96a5701724a19911, cn=RAJEEV SINGH
RAGHUVANSHI
Date: 2024.10.01 13:08:50 +05'30'

**Place: New Delhi
Date: 01-Oct-2024****Central Licencing Authority
Stamp****Annexure:****Details of new drug or investigational new drug:**

Names of the new drug or investigational new drug:	Glycopyrronium + Formoterol Fumarate + Budesonide (25mcg + 20mcg + 0.5mg) Inhalation Suspension
Therapeutic class:	Anticholinergic, Bronchodilator and Anti-inflammatory
Dosage form:	Inhalation Suspension (for nebulization)
Composition:	Each Smartule Contains:- Glycopyrrolate IP eq. to Glycopyrronium 25mcg Formoterol Fumarate Dihydrate IP eq. to Formoterol Fumarate 20mcg Budesonide IP 0.5mg
Indications:	Indicated as maintenance treatment for patients with chronic obstructive pulmonary disease (COPD).

Details of clinical trial site:

Names and address of clinical trial site:	As per annexure- A
Ethics committee details:	As per annexure- A
Name of principal investigator:	As per annexure- A

Annexure-APermission no.: **FDC-CT-06-37/2024**

S. No.	Name of PI	Site Name	Ethics Committee Name, Address & EC registration No.
1.	Dr. Vaibhav Daulat Pandharkar	Shree Hospital Criticare and Trauma Center Private Limited, Survey Number 7/3/B, Near Gulmohor Society, Kharadi, Pune-411014, Maharashtra, India.	Institutional Ethics Committee Sai Sneh Hospital and Diagnostic Centre. Opp. PMT Bus Depot, Pune Satara Road, Katraj, Pune, Maharashtra-411046 India. ECR/989/Inst/MH/2017/RR-20
2.	Dr. Keyur Brahme	Department of Medicine, Sir Sayajirao General (S.S.G) Hospital, Medical College Baroda, Anandpura, Jail road (Indira Avenue), Vadodara - 390001, Gujarat, India.	Institutional Ethics Committee For Human Research (IECHR), Medical College Baroda, Anandpura, Vadodara Gujarat - 390001, India. ECR/85/Inst/GJ/2013/RR-24
3.	Dr. Akash Balki	Shree Hospital & Critical Care Centre. 799, Om Nagar opp. Tajshree Building, Sakkardara Sq, Nagpur- 440009, Maharashtra, India.	Shree Hospital Ethics Committee Shree Hospital Unit, Plot No.786 A, 3rd Floor, Behind Shree Hospital & Critical Care Centre, Mirchi Bazaar, Umrer Road, Sakkardara, Sq, Nagpur - 440009, India. ECR/553/Inst/MH/2014/RR-20
4.	Dr. Anand Kumar	Department of Respiratory Medicine, GSVM Medical College, Swaroop Nagar, Kanpur- 208002, Uttar Pradesh- India	Ethics Committee GSVM Medical College Kanpur Swaroop Nagar Kanpur, Kanpur Nagar Uttar Pradesh - 208002, India. ECR/680/Inst/UP/2014/RR-20
5.	Dr. Manish Kumar Jain	Maharaja Agrasen Superspeciality Hospital, Sec - 7, Central spine, Vidyadhar Nagar, Jaipur - 302039, Rajasthan, India.	IEC, Maharaja Agrasen Hospital. Maharaja Agrasen Superspeciality Hospital, Central Spine, Agrasen Aspatal Marg Sector 7, Vidhyadhar Nagar, Jaipur Rajasthan - 302039, India. ECR/1222/Inst/RJ/2019/RR-22
6.	Dr. Pravin Dinkar Supe	Supre Heart and Diabetes Hospital & Research Centre, Opp. Adhar Asharam, Near Rungta School, Gharpure Ghat, Ashok Stambh, Nasik, Maharashtra (India)-422002.	Supre Hospital Ethics Committee Supre Heart and Diabetes Hospital & Research Centre, Opp. Adhar Asharam, Near Rungta School, Gharpure Ghat, Ashok Stambh, Nasik, Maharashtra -422002. ECR/272/Inst/MH/2013/RR-24
7.	Dr Sandeep Katiyar	Apollo Spectra Hospital (Apollo Speciality Hospital Pvt.Ltd), 14/138, Chunni Ganj, Kanpur-208001. UP, India	Apollo Specialty Hospital Kanpur Ethics Committee. Apollo Speciality Hospital Pvt.Ltd, 14/138, Chunni Ganj, Kanpur, Uttar Pradesh -208001. India. ECR/1327/INST/UP/2019
8.	Dr. Sanjay Khator	Excelcare Hospital, 103, Sanjay Nagar-A, Joshi Marg, Kalwar Road, Jhotwara, Jaipur, Rajasthan-302012, India.	Institutional Ethics Committee Sardarmal Khandaka Memorial Hospital, Room No-4, Ground Floor, Kalwar Road Hathoj, Jaipur, Rajasthan -302012 India. ECR/1032/Inst/RJ/2018/RR-21
9.	Dr. Himanshu Pophale	Ace Hospital & Research Centre, Sr No-32/2A Gulwani Maharaj Road, Erandwane, Pune, Maharashtra, India 411004.	Institutional Ethics Committee-ACE Hospital, Ace Hospital & Research Centre, SR No- 32/2A Gulwani Maharaj Road, Erandwane, Pune, Maharashtra, India 411004. ECR/1836/Inst/MH/2023

10.	Dr. Dinesh Agrawal	Marwari Hospital, Sati Jaymati Road, athgoan, Guwahati Kamrup, Metropolitan Assam-781008, Guwahati, Assam, India.	ECRC-HEC Marwari Hospital, Sati Jaymati Road, athgoan, Guwahati Kamrup, Metropolitan Assam-781008, Guwahati Assam. ECR/487/Inst/AS/2013/RR-19
11.	Dr. Shashi Bhushan	Victoria hospital, BMCRI, KR Road Fort Bangalore 560002, Karnataka, India.	Ethics Committee of BMCRI, Bangalore medical College and research Institute, Fort K R Road, Bangalore, Urban Karnataka- 560002. ECR/302/Inst/KA/2013/RR-20
12.	Dr. Rajkumar Gautam Nikalje	Life Point Multispeciality Hospital, 145/1 Mumbai Banglore Highway,Near hotel Sayaji, Wakad, Pune-411057, Maharashtra, India.	LPR Ethics Committee,145/1 Mumbai Banglore Highway,Near hotel Sayaji, Wakad,Pune- 411057, Maharashtra, India. ECR/751/Inst/MH/2015/RR-21
13.	Dr. Mahavir Satishchand Bagrecha	Dr.D.Y Patil Medical college, Hospital & Research Centre, Sant Tukaram Nagar Pimpri Pune-411018, Maharashtra, India.	Ethics Committee Dr. D.Y Patil Vidyapeth Santa Tukaram Nagar Pimpri Pune-411018. ECR/361/Inst/MAH/2013-RR-19. Application EC Reregistration Renewal Reference No. EC/RENEW/INST/2024/17148
14	Dr. Ajit Singh	SMS Medical College and Attached Hospital, Room No-16, First Floor Division of Allergy and Pulmonary Medicine, Dhanvantari OPD Block, SMS Medical College and attached Hospital, JLN Marg, Jaipur-302004, Rajasthan, India.	Ethics Committee SMS Medical College & Attached Hospital, JLN Marg, Jaipur-302004, Rajasthan,India. ECR/26/Inst/RJ/2013/RR-19
15.	Dr.Srikant Kashinath Malegaonkar	Department of Pulmonary Medicine, All India Institute of Medical Sciences (AIIMS),Plot No.2 ,Sector 20, MIHAN, Nagpur-441108, Maharashtra, India.	Institutional Ethics Committee, All India Institute of Medical Sciences (AIIMS), Nagpur. ECR/1392/Inst/MH/2020
16.	Dr. Raghavendra Reddy	Renova Neelima Hospital, Opp.Voltas Company, Sanathnagar, Hyderabad, 500018, Telangana, India.	Institutional Ethica Committee, Neelima Hospital Private ltd, 7-2-1735, Czech colony opp. Voltas company, Sanathanagar, Hyderabad- 500018. ECR/807/Inst/TG/2016/RR-24
17.	Dr. MaheshKumar Anandbhai Vaghani	Global Hospital, 4th floor, Nr.Navjivan Restaurant ,Sarhana Jakat Naka, Surat, Gujarat-395006, India.	Global Ethics Committee, Global Hospital 4th floor, Nr.Navjivan Restaurant, Sarhana Jakat Naka, Surat, Gujarat-395006, India. ECR/1616/INST/GJ/2021
18.	Dr Ashish Nikhare	Lata Mangeshkar Multispeciality Hospital, 5,Near YMCA Complex, MaharajBagh Road, Sitabuldi, Nagpur - 440012, Maharashtra, India.	Institutional Ethics Committee. NKP Salve Institute of Medical Sciences and Research Centre Lata Mangeshkar Hospital, Digdoh Hills, Hingna Road, Nagpur - 440019, Maharashtra, India. ECR/88/Inst/MH/2013/RR-19 Application EC Reregistration Renewal Reference No. EC/RENEW/INST/2024/16775

Place: New Delhi
Date: 01-Oct-2024

RAJEEV SINGH
RAGHUVANSHI
Central Licencing Authority
Stamp

Digitally signed by RAJEEV SINGH RAGHUVANSHI
DN: cn=RA, o=CENTRAL LICENSING AUTHORITY
ORGANIZATION=CENTRAL LICENSING AUTHORITY
2.5.4.29=C2E73961E0816A2C6A7C602019611568D4910E7
77804024E6663E3E90404E110992, cn=Date
serialNumber=657164E9F070488B38c0240616e73da12e1e1
26e09262017419011, cn=RAJEEV SINGH RAGHUVANSHI
Date: 2024.10.01 14:02:40 +05'30'